Currently 2 bullish, 1 bearish — becoming more polarizing.
Analysts are holding steady at 2 bullish to 1 bearish.
3 YouTube analysts cover Moderna, Inc. (MRNA).
3 analysts have covered MRNA so far…
MRNA broke out above prior resistance near $58, closing almost $62, with a double-bottom pattern and strong volume signaling a potential trend change.
After forming a double bottom, MRNA held support and broke out today, closing near $62 and taking out the prior highs around $58. This technical move, especially if money rotates into defensive areas, supports a bullish case.
MRNA can fit the ORB framework when the indexes are flushing and the stock is near key daily moving averages, because the “no-no” zones are described as occurring when the index is extended the other way.
MRNA is framed as a tradable ORB candidate specifically when the index action lines up with mean-reversion and snapback behavior around daily moving averages. The risk note is contextual: the approach warns against taking the same type of setups when the index tape is in the unfavorable “no-no” state.
MRNA appears to be preparing next-generation mRNA shots related to this “antivirus” threat (citing work from 2024 with Korea University), which he frames as evidence the vaccine program is implicitly tied to ongoing pathogen risk.
Next-generation mRNA vaccine development tied to 2024 research with Korea University is framed as implicit evidence that the vaccine program is linked to continuing pathogen risk rather than a standalone commercial opportunity.
No official filings surfaced for MRNA yet.
